Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking





Sector: Animal Feed

## **RESULT REVIEW Q2FY26**

Ajooni Biotech Limited

Declared On: 13 Nov 2025

RECOMMENDATION SNAPSHOT									
*CMP	MCap (Rsbn)	Recommendation	Target	Potential Upside					
Rs4.8	0.82	Buy	Rs9.0	88%					

<sup>\*</sup>as on 21st Nov, 2025

## **About the Company:**

Established in 2010, Ajooni Biotech Limited (ABL) is one of the leading pure veg animal feed, animal healthcare and feed supplements provider dedicated at improving the productivity of dairy farmers with focus on increasing livestock yields. It is involved in the compound, pure veg animal feed and pure veg feed supplements with a portfolio of wide range of quality feed products. Its portfolio has cattle feed, feed chips, camel feed, cotton oilcake, mustard oilcake and wide range of feed supplements to cover the entire life cycle of an animal. ABL is India's first pure veg cattle feed company to have Zero Effect, Zero Defect (ZED) gold process under the Prime Minister Make in India initiative. ABL has built mutually beneficial relationships with esteemed milk societies and milk processing companies. The key customers of the company include IFFCO Kisan, Patanjali, Paras, Mother Dairy, Saahaj, Balinee, Sakhi etc. Mr. Jasjot Singh is the Managing Director and CFO of the company.

## **Results: Quick Glance:**

- The net sales for the quarter reported growth of 23.4% to Rs317mn as compared to Rs257mn in Q2FY25
- The Ebitda margins for the quarter stood at 4.7% as compared to 3.0% in the comparative quarter last year
- The company reported profit of Rs9mn as compared to Rs6mn in the same quarter last year
- The EPS for the quarter stood at Rs0.08 as compared to Rs0.03 in the corresponding period of last year
- For H1FY26, the revenues came in at Rs630mn as compared to Rs514mn; growth of 22.6% while the PAT stood at Rs17mn as against Rs11mn. The EPS came in at Rs0.10 as against Rs0.03

#### **Financials:**

Performance (Q2FY26)											
Q2FY26 Result (Rs mn)	Sept-25	Sept-24	у-о-у	Jun-25	q-o-q	H1FY26	H1FY25	у-о-у	FY26E		
Total Revenue	317	257	23.4%	313	1.5%	630	514	22.6%	1434		
EBITDA	15	8	95.4%	7	-	22	17	28.1%	50		
Other Income	1	3	(52.4%)	6	(77.1%)	8	3	-	16		
Interest	2	1	-	1	-	3	2	22.7%	4		
Depreciation	2	2	8.8%	2	(1.2%)	5	4	10.0%	11		
Exceptional Items	0	0	-	0	-	0	0	-	0		
Тах	3	2	67.9%	2	22.7%	5	3	62.2%	12		
Net Profit	9	6	51.5%	8	19.3%	17	11	58.2%	39		

### **Outlook and Recommendations:**

The company has delivered strong performance for the quarter under review led by strong order inflows, steady execution and enhanced demand visibility due to repeat orders from established customers in the dairy segment. However, in the near term, external factors such as heavy rainfall and floods in Himachal Pradesh and Punjab in Q2FY26 can impact the cost and availability of key raw materials, which can put some stress on the gross margins and overall Ebitda in the upcoming quarters. The company has recently commissioned a new plant, which has successfully completed trial runs and is now moving into commercial production. This unit is expected to gradually ramp up over the next few months which can help mitigate the issues related to lesser production from the older plant to meet the high demand from the customers/clients which ABL could not earlier cater to; the old plant was running at almost full capacity utilisation. As production stabilises at the new facility, operating efficiencies are expected to improve, which can help the company better absorb cost pressures and support margin recovery over time. The ongoing research and development work on Moringa remains a key strategic lever, as any positive breakthrough in yield enhancement can meaningfully improve output quality and scale.

Please Turn Over Page No 01

Sector: Animal Feed RESULT REVIEW Q2FY26 Declared On: 13 Nov 2025

**Ajooni Biotech Limited** 

## **Outlook and Recommendations (contd.):**

During the quarter under review, the company has borrowed capital to fund its capex requirement, which is reflected in the CWIP, and while this increases near-term financial commitments, it also lays the foundation for higher long-term earning capacity as the new facility stabilises and volumes scale up. Additionally, the continued strengthening of the dealer and distributor network is expected to gradually improve market reach, reduce dependency on few large customers, and enhance supply chain resilience. Overall, while short-term margin pressures due to raw material uncertainty and weather-related disruptions cannot be ruled out, the medium-term trajectory appears constructive, supported by capacity expansion, improving operational efficiencies, and continuous product innovation, positioning the company for more stable and scalable growth once the new plant achieves optimal utilisation. These developments can take some time to fructify and we continue to maintain our target price of Rs9.

#### DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange/SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

- · PSBPL or its associates financial interest in the subject company: NO
- · Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- · PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- · PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- · Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- · PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- · The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is pr

#### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at the discretion of the clients to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

# Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

#### Compliance Officer:

Ms. Neha Oza,

Email: compliance @progressive shares.com,

Contact No.:022-40777500.

Grievance Officer:

Email: grievance cell@progressive shares.com